[go: up one dir, main page]

BR9708194A - Composição para a entrega e a produção in vivo de uma combinação de enzimas vetor composição para a produção in vivo de um análogo de nucleosidio trifosfato método para a destruição de células proliferativas processo de trifosforilação de uma análogo de nucleosidio utilização da nucleosidio difosfato quinase ácido nucléico e proteina codificada - Google Patents

Composição para a entrega e a produção in vivo de uma combinação de enzimas vetor composição para a produção in vivo de um análogo de nucleosidio trifosfato método para a destruição de células proliferativas processo de trifosforilação de uma análogo de nucleosidio utilização da nucleosidio difosfato quinase ácido nucléico e proteina codificada

Info

Publication number
BR9708194A
BR9708194A BR9708194A BR9708194A BR9708194A BR 9708194 A BR9708194 A BR 9708194A BR 9708194 A BR9708194 A BR 9708194A BR 9708194 A BR9708194 A BR 9708194A BR 9708194 A BR9708194 A BR 9708194A
Authority
BR
Brazil
Prior art keywords
composition
vivo production
nucleoside analog
nucleoside
triphosphorylation
Prior art date
Application number
BR9708194A
Other languages
English (en)
Inventor
Frances Blanche
Beatrice Cameron
Michel Coudert
Joel Crouzet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9708194A publication Critical patent/BR9708194A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211Thymidine kinase (2.7.1.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9708194A 1996-03-15 1997-03-12 Composição para a entrega e a produção in vivo de uma combinação de enzimas vetor composição para a produção in vivo de um análogo de nucleosidio trifosfato método para a destruição de células proliferativas processo de trifosforilação de uma análogo de nucleosidio utilização da nucleosidio difosfato quinase ácido nucléico e proteina codificada BR9708194A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603267A FR2746016B1 (fr) 1996-03-15 1996-03-15 Combinaisons d'enzymes pour la destruction de cellules proliferatives
PCT/FR1997/000436 WO1997035024A1 (fr) 1996-03-15 1997-03-12 Combinaisons d'enzymes pour la destruction des cellules proliferatives

Publications (1)

Publication Number Publication Date
BR9708194A true BR9708194A (pt) 1999-07-27

Family

ID=9490214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708194A BR9708194A (pt) 1996-03-15 1997-03-12 Composição para a entrega e a produção in vivo de uma combinação de enzimas vetor composição para a produção in vivo de um análogo de nucleosidio trifosfato método para a destruição de células proliferativas processo de trifosforilação de uma análogo de nucleosidio utilização da nucleosidio difosfato quinase ácido nucléico e proteina codificada

Country Status (15)

Country Link
US (1) US6518062B1 (pt)
EP (1) EP0910654A1 (pt)
JP (1) JP2000507814A (pt)
KR (1) KR20000064581A (pt)
AU (1) AU732432B2 (pt)
BR (1) BR9708194A (pt)
CA (1) CA2248629A1 (pt)
CZ (1) CZ291398A3 (pt)
FR (1) FR2746016B1 (pt)
HU (1) HUP9902320A3 (pt)
IL (1) IL126154A0 (pt)
NO (1) NO984132D0 (pt)
SK (1) SK124598A3 (pt)
WO (1) WO1997035024A1 (pt)
ZA (1) ZA972247B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386629A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
EP1914304A1 (en) * 1998-10-14 2008-04-23 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
WO2002056022A2 (en) * 2000-11-27 2002-07-18 Minerva Biotechnologies Corp Diagnostics, drug screening and treatment for cancer
EP1786474B1 (en) * 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
WO2008095027A2 (en) * 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
US10399291B2 (en) 2015-04-24 2019-09-03 Phi Biomed Co., Ltd. Smart contact lenses and smart glasses
KR102303140B1 (ko) 2018-05-30 2021-09-16 이화여자대학교 산학협력단 신규 바이페닐 유도체 화합물 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72122T1 (de) * 1987-04-24 1992-02-15 Wellcome Found Antivirale mischungen.
CN1151186A (zh) * 1994-05-02 1997-06-04 华盛顿大学 胸苷激酶突变体
FR2723962B1 (fr) * 1994-08-25 1996-10-31 Univ Paris Curie Hsv1-tk modifiee fonctionnelle
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases

Also Published As

Publication number Publication date
US6518062B1 (en) 2003-02-11
FR2746016A1 (fr) 1997-09-19
AU2164297A (en) 1997-10-10
IL126154A0 (en) 1999-05-09
AU732432B2 (en) 2001-04-26
NO984132L (no) 1998-09-08
CZ291398A3 (cs) 1998-12-16
WO1997035024A1 (fr) 1997-09-25
FR2746016B1 (fr) 1998-04-17
ZA972247B (en) 1997-09-17
KR20000064581A (ko) 2000-11-06
JP2000507814A (ja) 2000-06-27
HUP9902320A3 (en) 2001-05-28
CA2248629A1 (fr) 1997-09-25
NO984132D0 (no) 1998-09-08
SK124598A3 (en) 1999-03-12
HUP9902320A2 (hu) 1999-10-28
EP0910654A1 (fr) 1999-04-28

Similar Documents

Publication Publication Date Title
BR9508019A (pt) Neurotrofina pantrópica NT3 pantrópica ácido nucleico vetor de express o célula hospedeira método para fazer a neurotrofina pantrópica composiçao farmacêutica método para tratar uma desordem neural homodimero cavaltene pantrópica NGF pantrópico
ATE328069T1 (de) Phosphopantethenyltransferasen und deren verwendungen
BR9708194A (pt) Composição para a entrega e a produção in vivo de uma combinação de enzimas vetor composição para a produção in vivo de um análogo de nucleosidio trifosfato método para a destruição de células proliferativas processo de trifosforilação de uma análogo de nucleosidio utilização da nucleosidio difosfato quinase ácido nucléico e proteina codificada
AU8909998A (en) Methods and compositions for cloning nucleic acid molecules
HUP0200480A2 (hu) Enzimek új osztálya triacil-glicerin termelésére szolgáló bioszintetikus folyamatban és ezeket az enzimeket kódoló rekombináns DNS molekulák
CY2396B1 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame.
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO1997038729A8 (en) In vivo gene transfer methods for wound healing
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
ATE449183T1 (de) Verfahren zur herstellung von dipeptiden oder dipeptidderivaten.
IL129464A0 (en) Leaf-specific gene expression in transgenetic plants
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
GB9602025D0 (en) Nucleoside analogues
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
DE69626277D1 (de) Verfahren zur enzymatischen sulfatierung mit hilfe von 3'-phosphoadenosin-5'phosphosulfat und wiederverwendbare phosphorylierte adenosin-zwischen-produkte
GB2322132B (en) Keratinocyte growth factor-2 products
AU5832398A (en) Stress resistant plant in which cell death suppressing gene is introduced and method for producing the same
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
DE69803925D1 (de) Methode zur kalt-sterilisation von öfen des tunnel-typs im pharmazeutischen bereich und öfen zur anwendung dieser methode
DE69922248D1 (de) Integriertende protein-dna cochleateformulierungen und verfahren zur transformation von zellen
ATE407217T1 (de) Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s- adenosylmethionine (sam)
DE69815476D1 (de) Verfahren zur Herstellung von Trehalose und Zuckeralkoholen
FI19992095L (fi) Menetelmä ja entsyymivalmiste prosessiteollisuuteen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1882 DE 30/01/2007.